Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways

Abstract Background and purpose Although inhibition of epidermal growth factor receptor (EGFR) signaling during radiation led to improvement of tumor control and survival, novel strategies are needed to further improve the outcome of patients with locally advanced head and neck carcinoma. Because EG...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Radiotherapy and oncology 2012-11, Vol.105 (2), p.241-249
Hauptverfasser: Raju, Uma, Riesterer, Oliver, Wang, Zhi-Qiang, Molkentine, David P, Molkentine, Jessica M, Johnson, Faye M, Glisson, Bonnie, Milas, Luka, Ang, K. Kian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 249
container_issue 2
container_start_page 241
container_title Radiotherapy and oncology
container_volume 105
creator Raju, Uma
Riesterer, Oliver
Wang, Zhi-Qiang
Molkentine, David P
Molkentine, Jessica M
Johnson, Faye M
Glisson, Bonnie
Milas, Luka
Ang, K. Kian
description Abstract Background and purpose Although inhibition of epidermal growth factor receptor (EGFR) signaling during radiation led to improvement of tumor control and survival, novel strategies are needed to further improve the outcome of patients with locally advanced head and neck carcinoma. Because EGFR is known to interact with c-Src kinases, the present study investigated dasatinib (BMS-354825), an inhibitor of c-Src kinases, for its efficacy in enhancing radiosensitivity of human head and neck squamous cell carcinomas (HNSCC) in vitro and examined the underlying mechanisms for this effect. Materials and methods Six HNSCC lines were exposed to dasatinib, radiation, or both, and assessed for c-Src and EGFR expression, cell survival and colony forming ability. Among these cell lines, HN-5 and FaDu lines were analyzed for induction of apoptosis, cell cycle re-distribution and for nuclear localization of EGFR, γ-H2AX and 53BP1 proteins. Immuno-precipitation and Western blots were performed to analyze the levels and binding of proteins involved in cell survival, apoptosis and DNA repair pathways. Suppression of c-Src by siRNA and subsequent clonogenic assay was performed in HN-5 cells. Results All six HNSCC lines that were examined expressed high levels of c-Src. Two (HN-5 and MDA-183) expressed higher levels of EGFR than other lines. Dasatinib suppressed cell survival of all cell lines tested independent of c-Src or EGFR levels but enhanced the radiosensitivity of HN-5 and MDA-183. HN-5 and FaDu were analyzed further. Dasatinib suppressed phosphorylation of c-Src in both cell lines, but decreased repair of radiation-induced DNA damage in HN-5 cells only as evidenced by suppression of c-Abl and Nbs-1 activity, inhibition of the association between c-Src and EGFR or Her-2, prolongation of nuclear γ-H2AX and 53BP1 foci and inhibition of EGFR nuclear localization and its association with DNA-PKcs. Finally, partial suppression of c-Src resulted in a small increase in HN-5 cell radiosensitivity. Conclusions Our data demonstrate that dasatinib induces apoptosis and blocks DNA repair in EGFR-expressing HNSCC cells and improves radiotherapy outcome. These findings warrant further investigation using in vivo tumor models for potential translation into clinical testing.
doi_str_mv 10.1016/j.radonc.2012.08.010
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1239058307</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167814012003611</els_id><sourcerecordid>1239058307</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-700a0b1fbee01c557cf609eda5a7291b0bc161e83b387d99bace9c1d827f1a483</originalsourceid><addsrcrecordid>eNqFksFu1DAQhiMEotvCGyDkI4cmjJPdtXNBqloKSBUcgLNlO5Pu7GbtYDtdLc_FA-JoCwcunDyyv39-ef4pilccKg58_XZbBd15Z6saeF2BrIDDk2LBpWhLkFI8LRYZE6XkSzgrzmPcAkANjXhenNVNhpeyXhS_bnTUiRyZS6bZfhoSlTtyOiIjtyFDyYdc2YD5qmPZkjLuHYvoIiV6oHRk5piRhKHHQO6eHShtmJvsgDqwwVs90M-TyPcMR-ow7PXA7oM_ZLDXdvYIaHGcC-26uaHJwt3c7ebzVX4cNQU26rQ56GN8UTzr9RDx5eN5UXy_ff_t-mN59-XDp-uru9IuuUilANBgeG8QgdvVSth-DS12eqVF3XIDxvI1R9mYRoqubY222FreyVr0XC9lc1G8OfUdg_8xYUxqT9HiMGiHfoqK100LK9mAyOjyhNrgYwzYqzHQXoej4qDmvNRWnfJSc14KpMoRZNnrR4fJ7LH7K_oTUAbenQDM_3wgDCpaQmexozyxpDpP_3P4t4Edctw5lB0eMW79FFyeoeIqZo36Ou_MvDK8BmjWnDe_AR6Rwm4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1239058307</pqid></control><display><type>article</type><title>Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Raju, Uma ; Riesterer, Oliver ; Wang, Zhi-Qiang ; Molkentine, David P ; Molkentine, Jessica M ; Johnson, Faye M ; Glisson, Bonnie ; Milas, Luka ; Ang, K. Kian</creator><creatorcontrib>Raju, Uma ; Riesterer, Oliver ; Wang, Zhi-Qiang ; Molkentine, David P ; Molkentine, Jessica M ; Johnson, Faye M ; Glisson, Bonnie ; Milas, Luka ; Ang, K. Kian</creatorcontrib><description>Abstract Background and purpose Although inhibition of epidermal growth factor receptor (EGFR) signaling during radiation led to improvement of tumor control and survival, novel strategies are needed to further improve the outcome of patients with locally advanced head and neck carcinoma. Because EGFR is known to interact with c-Src kinases, the present study investigated dasatinib (BMS-354825), an inhibitor of c-Src kinases, for its efficacy in enhancing radiosensitivity of human head and neck squamous cell carcinomas (HNSCC) in vitro and examined the underlying mechanisms for this effect. Materials and methods Six HNSCC lines were exposed to dasatinib, radiation, or both, and assessed for c-Src and EGFR expression, cell survival and colony forming ability. Among these cell lines, HN-5 and FaDu lines were analyzed for induction of apoptosis, cell cycle re-distribution and for nuclear localization of EGFR, γ-H2AX and 53BP1 proteins. Immuno-precipitation and Western blots were performed to analyze the levels and binding of proteins involved in cell survival, apoptosis and DNA repair pathways. Suppression of c-Src by siRNA and subsequent clonogenic assay was performed in HN-5 cells. Results All six HNSCC lines that were examined expressed high levels of c-Src. Two (HN-5 and MDA-183) expressed higher levels of EGFR than other lines. Dasatinib suppressed cell survival of all cell lines tested independent of c-Src or EGFR levels but enhanced the radiosensitivity of HN-5 and MDA-183. HN-5 and FaDu were analyzed further. Dasatinib suppressed phosphorylation of c-Src in both cell lines, but decreased repair of radiation-induced DNA damage in HN-5 cells only as evidenced by suppression of c-Abl and Nbs-1 activity, inhibition of the association between c-Src and EGFR or Her-2, prolongation of nuclear γ-H2AX and 53BP1 foci and inhibition of EGFR nuclear localization and its association with DNA-PKcs. Finally, partial suppression of c-Src resulted in a small increase in HN-5 cell radiosensitivity. Conclusions Our data demonstrate that dasatinib induces apoptosis and blocks DNA repair in EGFR-expressing HNSCC cells and improves radiotherapy outcome. These findings warrant further investigation using in vivo tumor models for potential translation into clinical testing.</description><identifier>ISSN: 0167-8140</identifier><identifier>EISSN: 1879-0887</identifier><identifier>DOI: 10.1016/j.radonc.2012.08.010</identifier><identifier>PMID: 23010482</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Active Transport, Cell Nucleus - drug effects ; Apoptosis - radiation effects ; c-Src ; Carcinoma, Squamous Cell - radiotherapy ; Cell Cycle ; Cell Nucleus - metabolism ; Dasatinib ; DNA repair ; DNA Repair - drug effects ; EGFR ; ErbB Receptors - analysis ; ErbB Receptors - metabolism ; Focal Adhesion Protein-Tyrosine Kinases - metabolism ; Head and neck cancer ; Head and Neck Neoplasms - radiotherapy ; Hematology, Oncology and Palliative Medicine ; Humans ; Protein Kinase Inhibitors - pharmacology ; Pyrimidines - pharmacology ; Radiation sensitivity ; Radiation Tolerance - drug effects ; Squamous Cell Carcinoma of Head and Neck ; src-Family Kinases - analysis ; src-Family Kinases - metabolism ; Thiazoles - pharmacology</subject><ispartof>Radiotherapy and oncology, 2012-11, Vol.105 (2), p.241-249</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2012 Elsevier Ireland Ltd</rights><rights>Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-700a0b1fbee01c557cf609eda5a7291b0bc161e83b387d99bace9c1d827f1a483</citedby><cites>FETCH-LOGICAL-c417t-700a0b1fbee01c557cf609eda5a7291b0bc161e83b387d99bace9c1d827f1a483</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0167814012003611$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23010482$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raju, Uma</creatorcontrib><creatorcontrib>Riesterer, Oliver</creatorcontrib><creatorcontrib>Wang, Zhi-Qiang</creatorcontrib><creatorcontrib>Molkentine, David P</creatorcontrib><creatorcontrib>Molkentine, Jessica M</creatorcontrib><creatorcontrib>Johnson, Faye M</creatorcontrib><creatorcontrib>Glisson, Bonnie</creatorcontrib><creatorcontrib>Milas, Luka</creatorcontrib><creatorcontrib>Ang, K. Kian</creatorcontrib><title>Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways</title><title>Radiotherapy and oncology</title><addtitle>Radiother Oncol</addtitle><description>Abstract Background and purpose Although inhibition of epidermal growth factor receptor (EGFR) signaling during radiation led to improvement of tumor control and survival, novel strategies are needed to further improve the outcome of patients with locally advanced head and neck carcinoma. Because EGFR is known to interact with c-Src kinases, the present study investigated dasatinib (BMS-354825), an inhibitor of c-Src kinases, for its efficacy in enhancing radiosensitivity of human head and neck squamous cell carcinomas (HNSCC) in vitro and examined the underlying mechanisms for this effect. Materials and methods Six HNSCC lines were exposed to dasatinib, radiation, or both, and assessed for c-Src and EGFR expression, cell survival and colony forming ability. Among these cell lines, HN-5 and FaDu lines were analyzed for induction of apoptosis, cell cycle re-distribution and for nuclear localization of EGFR, γ-H2AX and 53BP1 proteins. Immuno-precipitation and Western blots were performed to analyze the levels and binding of proteins involved in cell survival, apoptosis and DNA repair pathways. Suppression of c-Src by siRNA and subsequent clonogenic assay was performed in HN-5 cells. Results All six HNSCC lines that were examined expressed high levels of c-Src. Two (HN-5 and MDA-183) expressed higher levels of EGFR than other lines. Dasatinib suppressed cell survival of all cell lines tested independent of c-Src or EGFR levels but enhanced the radiosensitivity of HN-5 and MDA-183. HN-5 and FaDu were analyzed further. Dasatinib suppressed phosphorylation of c-Src in both cell lines, but decreased repair of radiation-induced DNA damage in HN-5 cells only as evidenced by suppression of c-Abl and Nbs-1 activity, inhibition of the association between c-Src and EGFR or Her-2, prolongation of nuclear γ-H2AX and 53BP1 foci and inhibition of EGFR nuclear localization and its association with DNA-PKcs. Finally, partial suppression of c-Src resulted in a small increase in HN-5 cell radiosensitivity. Conclusions Our data demonstrate that dasatinib induces apoptosis and blocks DNA repair in EGFR-expressing HNSCC cells and improves radiotherapy outcome. These findings warrant further investigation using in vivo tumor models for potential translation into clinical testing.</description><subject>Active Transport, Cell Nucleus - drug effects</subject><subject>Apoptosis - radiation effects</subject><subject>c-Src</subject><subject>Carcinoma, Squamous Cell - radiotherapy</subject><subject>Cell Cycle</subject><subject>Cell Nucleus - metabolism</subject><subject>Dasatinib</subject><subject>DNA repair</subject><subject>DNA Repair - drug effects</subject><subject>EGFR</subject><subject>ErbB Receptors - analysis</subject><subject>ErbB Receptors - metabolism</subject><subject>Focal Adhesion Protein-Tyrosine Kinases - metabolism</subject><subject>Head and neck cancer</subject><subject>Head and Neck Neoplasms - radiotherapy</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Pyrimidines - pharmacology</subject><subject>Radiation sensitivity</subject><subject>Radiation Tolerance - drug effects</subject><subject>Squamous Cell Carcinoma of Head and Neck</subject><subject>src-Family Kinases - analysis</subject><subject>src-Family Kinases - metabolism</subject><subject>Thiazoles - pharmacology</subject><issn>0167-8140</issn><issn>1879-0887</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFksFu1DAQhiMEotvCGyDkI4cmjJPdtXNBqloKSBUcgLNlO5Pu7GbtYDtdLc_FA-JoCwcunDyyv39-ef4pilccKg58_XZbBd15Z6saeF2BrIDDk2LBpWhLkFI8LRYZE6XkSzgrzmPcAkANjXhenNVNhpeyXhS_bnTUiRyZS6bZfhoSlTtyOiIjtyFDyYdc2YD5qmPZkjLuHYvoIiV6oHRk5piRhKHHQO6eHShtmJvsgDqwwVs90M-TyPcMR-ow7PXA7oM_ZLDXdvYIaHGcC-26uaHJwt3c7ebzVX4cNQU26rQ56GN8UTzr9RDx5eN5UXy_ff_t-mN59-XDp-uru9IuuUilANBgeG8QgdvVSth-DS12eqVF3XIDxvI1R9mYRoqubY222FreyVr0XC9lc1G8OfUdg_8xYUxqT9HiMGiHfoqK100LK9mAyOjyhNrgYwzYqzHQXoej4qDmvNRWnfJSc14KpMoRZNnrR4fJ7LH7K_oTUAbenQDM_3wgDCpaQmexozyxpDpP_3P4t4Edctw5lB0eMW79FFyeoeIqZo36Ou_MvDK8BmjWnDe_AR6Rwm4</recordid><startdate>20121101</startdate><enddate>20121101</enddate><creator>Raju, Uma</creator><creator>Riesterer, Oliver</creator><creator>Wang, Zhi-Qiang</creator><creator>Molkentine, David P</creator><creator>Molkentine, Jessica M</creator><creator>Johnson, Faye M</creator><creator>Glisson, Bonnie</creator><creator>Milas, Luka</creator><creator>Ang, K. Kian</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20121101</creationdate><title>Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways</title><author>Raju, Uma ; Riesterer, Oliver ; Wang, Zhi-Qiang ; Molkentine, David P ; Molkentine, Jessica M ; Johnson, Faye M ; Glisson, Bonnie ; Milas, Luka ; Ang, K. Kian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-700a0b1fbee01c557cf609eda5a7291b0bc161e83b387d99bace9c1d827f1a483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Active Transport, Cell Nucleus - drug effects</topic><topic>Apoptosis - radiation effects</topic><topic>c-Src</topic><topic>Carcinoma, Squamous Cell - radiotherapy</topic><topic>Cell Cycle</topic><topic>Cell Nucleus - metabolism</topic><topic>Dasatinib</topic><topic>DNA repair</topic><topic>DNA Repair - drug effects</topic><topic>EGFR</topic><topic>ErbB Receptors - analysis</topic><topic>ErbB Receptors - metabolism</topic><topic>Focal Adhesion Protein-Tyrosine Kinases - metabolism</topic><topic>Head and neck cancer</topic><topic>Head and Neck Neoplasms - radiotherapy</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Pyrimidines - pharmacology</topic><topic>Radiation sensitivity</topic><topic>Radiation Tolerance - drug effects</topic><topic>Squamous Cell Carcinoma of Head and Neck</topic><topic>src-Family Kinases - analysis</topic><topic>src-Family Kinases - metabolism</topic><topic>Thiazoles - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raju, Uma</creatorcontrib><creatorcontrib>Riesterer, Oliver</creatorcontrib><creatorcontrib>Wang, Zhi-Qiang</creatorcontrib><creatorcontrib>Molkentine, David P</creatorcontrib><creatorcontrib>Molkentine, Jessica M</creatorcontrib><creatorcontrib>Johnson, Faye M</creatorcontrib><creatorcontrib>Glisson, Bonnie</creatorcontrib><creatorcontrib>Milas, Luka</creatorcontrib><creatorcontrib>Ang, K. Kian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Radiotherapy and oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raju, Uma</au><au>Riesterer, Oliver</au><au>Wang, Zhi-Qiang</au><au>Molkentine, David P</au><au>Molkentine, Jessica M</au><au>Johnson, Faye M</au><au>Glisson, Bonnie</au><au>Milas, Luka</au><au>Ang, K. Kian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways</atitle><jtitle>Radiotherapy and oncology</jtitle><addtitle>Radiother Oncol</addtitle><date>2012-11-01</date><risdate>2012</risdate><volume>105</volume><issue>2</issue><spage>241</spage><epage>249</epage><pages>241-249</pages><issn>0167-8140</issn><eissn>1879-0887</eissn><abstract>Abstract Background and purpose Although inhibition of epidermal growth factor receptor (EGFR) signaling during radiation led to improvement of tumor control and survival, novel strategies are needed to further improve the outcome of patients with locally advanced head and neck carcinoma. Because EGFR is known to interact with c-Src kinases, the present study investigated dasatinib (BMS-354825), an inhibitor of c-Src kinases, for its efficacy in enhancing radiosensitivity of human head and neck squamous cell carcinomas (HNSCC) in vitro and examined the underlying mechanisms for this effect. Materials and methods Six HNSCC lines were exposed to dasatinib, radiation, or both, and assessed for c-Src and EGFR expression, cell survival and colony forming ability. Among these cell lines, HN-5 and FaDu lines were analyzed for induction of apoptosis, cell cycle re-distribution and for nuclear localization of EGFR, γ-H2AX and 53BP1 proteins. Immuno-precipitation and Western blots were performed to analyze the levels and binding of proteins involved in cell survival, apoptosis and DNA repair pathways. Suppression of c-Src by siRNA and subsequent clonogenic assay was performed in HN-5 cells. Results All six HNSCC lines that were examined expressed high levels of c-Src. Two (HN-5 and MDA-183) expressed higher levels of EGFR than other lines. Dasatinib suppressed cell survival of all cell lines tested independent of c-Src or EGFR levels but enhanced the radiosensitivity of HN-5 and MDA-183. HN-5 and FaDu were analyzed further. Dasatinib suppressed phosphorylation of c-Src in both cell lines, but decreased repair of radiation-induced DNA damage in HN-5 cells only as evidenced by suppression of c-Abl and Nbs-1 activity, inhibition of the association between c-Src and EGFR or Her-2, prolongation of nuclear γ-H2AX and 53BP1 foci and inhibition of EGFR nuclear localization and its association with DNA-PKcs. Finally, partial suppression of c-Src resulted in a small increase in HN-5 cell radiosensitivity. Conclusions Our data demonstrate that dasatinib induces apoptosis and blocks DNA repair in EGFR-expressing HNSCC cells and improves radiotherapy outcome. These findings warrant further investigation using in vivo tumor models for potential translation into clinical testing.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>23010482</pmid><doi>10.1016/j.radonc.2012.08.010</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0167-8140
ispartof Radiotherapy and oncology, 2012-11, Vol.105 (2), p.241-249
issn 0167-8140
1879-0887
language eng
recordid cdi_proquest_miscellaneous_1239058307
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Active Transport, Cell Nucleus - drug effects
Apoptosis - radiation effects
c-Src
Carcinoma, Squamous Cell - radiotherapy
Cell Cycle
Cell Nucleus - metabolism
Dasatinib
DNA repair
DNA Repair - drug effects
EGFR
ErbB Receptors - analysis
ErbB Receptors - metabolism
Focal Adhesion Protein-Tyrosine Kinases - metabolism
Head and neck cancer
Head and Neck Neoplasms - radiotherapy
Hematology, Oncology and Palliative Medicine
Humans
Protein Kinase Inhibitors - pharmacology
Pyrimidines - pharmacology
Radiation sensitivity
Radiation Tolerance - drug effects
Squamous Cell Carcinoma of Head and Neck
src-Family Kinases - analysis
src-Family Kinases - metabolism
Thiazoles - pharmacology
title Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T20%3A26%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dasatinib,%20a%20multi-kinase%20inhibitor%20increased%20radiation%20sensitivity%20by%20interfering%20with%20nuclear%20localization%20of%20epidermal%20growth%20factor%20receptor%20and%20by%20blocking%20DNA%20repair%20pathways&rft.jtitle=Radiotherapy%20and%20oncology&rft.au=Raju,%20Uma&rft.date=2012-11-01&rft.volume=105&rft.issue=2&rft.spage=241&rft.epage=249&rft.pages=241-249&rft.issn=0167-8140&rft.eissn=1879-0887&rft_id=info:doi/10.1016/j.radonc.2012.08.010&rft_dat=%3Cproquest_cross%3E1239058307%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1239058307&rft_id=info:pmid/23010482&rft_els_id=S0167814012003611&rfr_iscdi=true